Better plans and more powerful evidence are needed in the research and treatment of chronic hepatitis B in China.

China has the first largest global pool of chronic hepatitis B (CHB) infection. With the implementation of comprehensive intervention of neonatal vaccination based on national strategy, some achievements have been made in control of hepatitis B in China. However, some problems remain unresolved in the research field as well as management of CHB. Currently, empirical therapy, poor study design, inefficient management, low compliance rate of patients, lack of public awareness and economic factor hampers the research and treatment of CHB in China. We propose that China should take more effective measures to improve the study quality, social management, the relief of economic burden for the needed patients, public awareness, evidence-based policies and medicine, supervision for clinical practice, diagnostics ability and laboratory quality, the compliance of patients, and the quality of Traditional Chinese Medicine (TCM) in the management of CHB infection in the future.